Nivelles, Belgium / Hyderabad, India – 22 June 2026 – Quantoom (operating as Phoenix Biosciences SA) and Nucelion Therapeutics Private Limited today announced the signing of a Memorandum of Understanding (MoU) to explore a preferred RNA contract development and manufacturing (CDMO) partnership in India.

Under the MoU, Nucelion would operate Quantoom’s N-Force platform technologies to provide both research-grade and GMP-grade RNA manufacturing services to clients across human therapeutics and animal health. The collaboration reflects a shared view of the significant and growing opportunity for RNA-based products in India and the broader Asia-Pacific region — spanning mRNA therapeutics, RNA-based vaccines, oligonucleotide therapies, and veterinary applications.

Quantoom’s N-Force toolbox supports the rapid development of (sa)mRNA as a drug modality — from design through RNA production and encapsulation — via its Ntensify® equipment and consumables, reagent pre-mixes, and Ncapsulate® QCX delivery technology. Through the intended partnership, Nucelion aims to establish and scale RNA CDMO capability at its facilities in India, supported by Quantoom technology transfer and technical expertise.

“By bringing the N-Force platform to Nucelion’s facilities, we’re not just transferring technology — we’re helping establish local RNA capacity where it’s needed most. We see enormous potential across India and the wider Asia-Pacific region, and we’re excited to explore this collaboration.” said José CASTILLO – CEO of Quantoom.

Dr. Raghu Malapaka, CBO of Nucelion said“At Nucelion, we are building world-class infrastructure to advance the next generation of cell & gene and RNA based therapies into clinics. Our state-of-the-art GMP facility in Genome Valley is being purpose-built to host transformative platforms like Quantoom’s N-Force. This partnership is a significant milestone in that journey, and a testament to our shared commitment to making cutting-edge biologics affordable and accessible in a timely manner to patients everywhere in the world.”

About Quantoom Biosciences

Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization. Quantoom Biosciences is a trade name of Phoenix Biosciences SA. For more information about Quantoom Biosciences, visit www.quantoom.com

About Nucelion Therapeutics

Nucelion Therapeutics Private Limited is a next-generation Cell & Gene Therapy (CGT) CDMO purpose-built to help innovators accelerate their journey from discovery to clinical impact. Backed by deep expertise across viral vectors (AAV, Lentivirus), advanced cell therapies (CAR-T, NK, iPSC-derived), exosomes, and non-viral gene delivery platforms, Nucelion brings scientific precision and operational excellence under one roof. The company is expanding its capabilities to include RNA manufacturing services spanning both human therapeutics and animal health — positioning itself as a comprehensive partner across the evolving landscape of advanced biologics. Nucelion operates from a state-of-the-art 30,000 sq. ft. GMP facility in Genome Valley, Hyderabad — India’s premier biotechnology hub and a globally recognized center for life sciences innovation. A wholly owned subsidiary of Bharat Biotech International Limited, a global leader in vaccines and biologics, Nucelion combines the agility of a specialized CDMO with the credibility and infrastructure of one of India’s most respected bioscience enterprises.

Media contact

Nicolas DANTINNE – Marcom manager @ Quantoom – n.dantinne@quantoom.com

Raghu MALAPAKA – CBO @ Nucelion – raghu.m@nucelion.com